{
    "id": 17574,
    "fullName": "PIK3CB D1067Y",
    "impact": "missense",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "PIK3CB D1067Y lies within the PI3K/PI4K domain of the Pik3cb protein (UniProt.org). D1067Y results in increased Pik3cb kinase activity, activation of Akt signaling, and is transforming in cell culture (PMID: 26759240, PMID: 29533785).",
            "references": [
                {
                    "id": 4509,
                    "pubMedId": 26759240,
                    "title": "Activating Mutations in PIK3CB Confer Resistance to PI3K Inhibition and Define a Novel Oncogenic Role for p110\u03b2.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26759240"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 11238,
                    "pubMedId": 29533785,
                    "title": "Systematic Functional Annotation of Somatic Mutations in Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29533785"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 5291,
        "geneSymbol": "PIK3CB",
        "terms": [
            "PIK3CB",
            "P110BETA",
            "PI3K",
            "PI3KBETA",
            "PIK3C1"
        ]
    },
    "variant": "D1067Y",
    "createDate": "02/02/2016",
    "updateDate": "04/30/2018",
    "referenceTranscriptCoordinates": {
        "id": 174497,
        "transcript": "NM_006219",
        "gDna": "chr3:g.138655403C>A",
        "cDna": "c.3199G>T",
        "protein": "p.D1067Y",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 4372,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, breast cancer cell lines overexpressing PIK3CB D1067Y demonstrated reduced sensitivity to GDC-0941-induced growth inhibition in culture (PMID: 26759240).",
            "molecularProfile": {
                "id": 17877,
                "profileName": "PIK3CB D1067Y"
            },
            "therapy": {
                "id": 749,
                "therapyName": "Pictilisib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 4509,
                    "pubMedId": 26759240,
                    "title": "Activating Mutations in PIK3CB Confer Resistance to PI3K Inhibition and Define a Novel Oncogenic Role for p110\u03b2.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26759240"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 4373,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, breast cancer cell lines overexpressing PIK3CB D1067Y demonstrated reduced sensitivity to Taselisib (GDC-0032)-induced growth inhibition in culture (PMID: 26759240).",
            "molecularProfile": {
                "id": 17877,
                "profileName": "PIK3CB D1067Y"
            },
            "therapy": {
                "id": 1016,
                "therapyName": "Taselisib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 4509,
                    "pubMedId": 26759240,
                    "title": "Activating Mutations in PIK3CB Confer Resistance to PI3K Inhibition and Define a Novel Oncogenic Role for p110\u03b2.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26759240"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 4374,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, breast cancer cell lines overexpressing PIK3CB D1067Y demonstrated reduced sensitivity to TGX-221-induced growth inhibition in culture (PMID: 26759240).",
            "molecularProfile": {
                "id": 17877,
                "profileName": "PIK3CB D1067Y"
            },
            "therapy": {
                "id": 2514,
                "therapyName": "TGX-221",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 4509,
                    "pubMedId": 26759240,
                    "title": "Activating Mutations in PIK3CB Confer Resistance to PI3K Inhibition and Define a Novel Oncogenic Role for p110\u03b2.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26759240"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 4375,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Ipatasertib (GDC-0068) inhibited growth of breast cancer cell lines overexpressing PIK3CB D1067Y in culture (PMID: 26759240).",
            "molecularProfile": {
                "id": 17877,
                "profileName": "PIK3CB D1067Y"
            },
            "therapy": {
                "id": 747,
                "therapyName": "Ipatasertib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4509,
                    "pubMedId": 26759240,
                    "title": "Activating Mutations in PIK3CB Confer Resistance to PI3K Inhibition and Define a Novel Oncogenic Role for p110\u03b2.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26759240"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4376,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GDC-0349 inhibited growth of breast cancer cell lines overexpressing PIK3CB D1067Y in culture (PMID: 26759240).",
            "molecularProfile": {
                "id": 17877,
                "profileName": "PIK3CB D1067Y"
            },
            "therapy": {
                "id": 1017,
                "therapyName": "GDC-0349",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4509,
                    "pubMedId": 26759240,
                    "title": "Activating Mutations in PIK3CB Confer Resistance to PI3K Inhibition and Define a Novel Oncogenic Role for p110\u03b2.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26759240"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 17877,
            "profileName": "PIK3CB D1067Y",
            "profileTreatmentApproaches": [
                {
                    "id": 7715,
                    "name": "PI3K Inhibitor (Pan)",
                    "profileName": "PIK3CB D1067Y"
                },
                {
                    "id": 7716,
                    "name": "PIK3CB inhibitor",
                    "profileName": "PIK3CB D1067Y"
                }
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 174499,
            "transcript": "XM_006713659",
            "gDna": "chr3:g.138655403C>A",
            "cDna": "c.3199G>T",
            "protein": "p.D1067Y",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 174500,
            "transcript": "XM_011512895",
            "gDna": "chr3:g.138655403C>A",
            "cDna": "c.3199G>T",
            "protein": "p.D1067Y",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 174498,
            "transcript": "XM_005247530",
            "gDna": "chr3:g.138655403C>A",
            "cDna": "c.3199G>T",
            "protein": "p.D1067Y",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 174497,
            "transcript": "NM_006219",
            "gDna": "chr3:g.138655403C>A",
            "cDna": "c.3199G>T",
            "protein": "p.D1067Y",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 174501,
            "transcript": "XM_017006619",
            "gDna": "chr3:g.138655403C>A",
            "cDna": "c.3199G>T",
            "protein": "p.D1067Y",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}